Litigation Details for LEO Pharma A/S v. Actavis Laboratories UT, Inc. (D. Del. 2016)

LEO Pharma A/S v. Actavis Laboratories UT, Inc. (D. Del. 2016)

Docket	1:16-cv-00333-JFB-SR	Date Filed	2016-05-06
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To	Judge Sherry R. Fallon
Patents	7,410,656; 8,278,292; 8,372,827; 8,372,828; 8,377,919; 8,536,163; 8,716,271; 8,735,375
Link to Docket	External link to docket

Details for LEO Pharma A/S v. Actavis Laboratories UT, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-06	266		infringement often patents: U.S. Patent Nos. 7,410,656 ("the '656 patent"), 8,278,292 (…163 patent"), 8,716,271 ("the '271 patent"), 8,735,375 ("the '375 patent"…the "patents-in-suit"). (Id at ,r 8) The '084 patent and the '698 patent, identified…prior art U.S. Patent No. 7,378,445 ("the '445 patent") to the U.S. Patent and Trademark … entire patent portfolio, including the '445 patent and U.S. Patent No. 7,449,492 ("the '	External link to document

LEO Pharma v. Actavis Laboratories UT: Patent Litigation Summary and Generic Entry Analysis

Last updated: September 25, 2026

LEO Pharma A/S v. Actavis Laboratories UT, Inc., No. 1:16-cv-00333-JFB-SR, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Actavis’s proposed generic version of Enstilar, LEO Pharma’s calcipotriene and betamethasone dipropionate topical foam. The dispute centered on LEO Pharma’s formulation patent covering the combination of the two active ingredients in a substantially nonaqueous foam vehicle.

The case formed part of the broader generic challenge to LEO Pharma’s Enstilar franchise. The asserted patent estate later became the subject of related litigation involving Teva, including Federal Circuit review of the obviousness issues surrounding the same formulation technology.

What drug and formulation were at issue in LEO Pharma v. Actavis?

The litigation concerned Enstilar Foam, a prescription topical product containing:

Product	Active ingredients	Dosage form	Sponsor
Enstilar Foam	Calcipotriene and betamethasone dipropionate	Topical aerosol foam	LEO Pharma A/S

Enstilar is approved for the topical treatment of plaque psoriasis in patients aged 18 years and older. Calcipotriene is a vitamin D analog, while betamethasone dipropionate is a corticosteroid. The product combines both agents in a foam formulation designed to improve delivery and stability.

The FDA approved Enstilar under NDA 207589 in October 2015. LEO Pharma filed the Delaware action after receiving notice that Actavis had submitted an Abbreviated New Drug Application seeking approval of a generic calcipotriene and betamethasone dipropionate foam before expiration of LEO’s listed patent rights.[1]

What patents protected Enstilar in the Actavis litigation?

The principal patent associated with the litigation was U.S. Patent No. 8,865,688, titled “Pharmaceutical composition comprising calcipotriol and betamethasone dipropionate.” The patent was assigned to LEO Pharma A/S and claimed pharmaceutical compositions containing the two active ingredients in a formulation designed to maintain chemical stability.

A related patent, U.S. Patent No. 9,125,910, also covered aspects of the calcipotriene and betamethasone dipropionate formulation technology and was associated with the Enstilar patent estate.

Key patent and formulation information

Patent	Subject matter	Relevance
U.S. Patent No. 8,865,688	Calcipotriene and betamethasone dipropionate pharmaceutical composition	Principal patent in the formulation dispute
U.S. Patent No. 9,125,910	Related formulation technology	Part of the broader Enstilar patent portfolio
NDA 207589	Enstilar Foam	FDA approval covering the branded product

The central technical issue was not simply the presence of the two active ingredients. It was whether the particular combination, vehicle, solvent system, and stability characteristics represented a patentable formulation advance over earlier calcipotriene and corticosteroid products.

What were LEO Pharma’s infringement allegations?

LEO Pharma alleged that Actavis’s ANDA product would infringe claims of the asserted Enstilar formulation patent under the Hatch-Waxman framework. The complaint sought the standard remedies available in an ANDA case, including:

• A declaration that the asserted claims were valid and enforceable.
• A finding that Actavis’s proposed product would infringe.
• An injunction preventing FDA approval of the ANDA before patent expiration.
• A statutory stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

The litigation was based on Actavis’s Paragraph IV certification. That certification represented Actavis’s position that the relevant patent claims were invalid, unenforceable, or would not be infringed by the proposed generic product.

What defenses did Actavis raise?

Actavis’s principal defenses in this type of litigation were invalidity and noninfringement. The validity issues focused on whether the claimed formulation would have been obvious to a person of ordinary skill in the art based on prior calcipotriene, betamethasone, foam, and topical-combination products.

The relevant prior-art analysis included:

1. Earlier products containing calcipotriene and betamethasone dipropionate.
2. Prior topical foam formulations.
3. Known concerns regarding the chemical instability of calcipotriene.
4. Formulation techniques used to stabilize corticosteroid and vitamin D analog combinations.
5. The level of predictability in selecting excipients and solvent systems.

Actavis’s noninfringement position would have depended on the specific composition of its proposed ANDA product and whether it satisfied the asserted claim limitations, including the claimed active-ingredient concentrations, vehicle characteristics, and stability requirements.

How did the formulation patent differ from ordinary combination-product protection?

LEO Pharma’s patent position was stronger than a basic claim directed only to combining two known active ingredients. The commercial and litigation value came from the formulation architecture.

What formulation characteristics mattered?

The asserted patent claims addressed the interaction between:

• Calcipotriene concentration.
• Betamethasone dipropionate concentration.
• The vehicle used to carry the active ingredients.
• The presence or absence of water.
• Solvent selection.
• Chemical stability during storage.
• Delivery as a topical foam.

Calcipotriene presented a recognized stability challenge. A formulation that combined calcipotriene with betamethasone dipropionate while maintaining stability could support a nonobviousness argument even where each active ingredient was individually known.

The later Federal Circuit litigation involving the same patent family emphasized that formulation stability and the claimed solution to the stability problem were central to the obviousness analysis.[2]

What was the procedural status of the Actavis case?

The action was filed in 2016 in the District of Delaware before Judge Joseph F. Bataillon, with Magistrate Judge Sherry R. Fallon assigned for referral and pretrial matters. The case was docketed as No. 1:16-cv-00333-JFB-SR.

The public docket identifies the case as a pharmaceutical patent action arising from an ANDA challenge to Enstilar. The action did not produce the same widely cited merits opinion as the later LEO Pharma v. Teva proceeding. The principal precedential development concerning the ’688 patent came from the Teva litigation, in which the Federal Circuit addressed the obviousness analysis for the Enstilar formulation patent.[2]

Litigation timeline

Date	Event
October 2015	FDA approved Enstilar Foam under NDA 207589
2016	LEO Pharma filed the Delaware Hatch-Waxman action against Actavis
2016 onward	The parties litigated the Paragraph IV challenge and formulation patent issues
Later proceedings	Related litigation involving the same patent technology produced Federal Circuit guidance on obviousness

The case record should be analyzed separately from the later LEO Pharma v. Teva appellate decision. A ruling in the Teva action may be relevant to the patent’s validity, but it is not a substitute for the docket-specific disposition in the Actavis action.

What was the Orange Book status of Enstilar?

Enstilar’s patent protection was based principally on formulation patents rather than a new chemical entity patent. The Orange Book listings for Enstilar identified patent rights covering the approved product and its formulation technology.

Orange Book and regulatory implications

An ANDA applicant seeking approval before expiration of a listed patent generally must make one of four certifications:

• Paragraph I: No patent information has been submitted.
• Paragraph II: The patent has expired.
• Paragraph III: The applicant will wait until patent expiration.
• Paragraph IV: The patent is invalid, unenforceable, or will not be infringed.

Actavis’s Paragraph IV certification triggered the patent action. Filing the suit within the statutory period ordinarily creates a 30-month stay of FDA approval, subject to statutory exceptions and court action.

Because Enstilar is a topical foam rather than a biologic, biosimilar rules do not apply. The relevant pathway was the ANDA pathway for generic drugs, not the abbreviated biologics pathway under the Public Health Service Act.

When could generic Enstilar enter the market?

Generic entry depended on four factors:

1. The expiration dates of the Orange Book-listed patents.
2. The outcome of the Paragraph IV litigation.
3. Any settlement or license granted by LEO Pharma.
4. FDA approval of Actavis’s ANDA, including compliance with product-specific requirements.

Patent litigation did not automatically establish a commercial launch date. A generic applicant could enter after a final judgment of invalidity or noninfringement, after patent expiration, or under an authorized settlement that permitted an earlier launch.

The case therefore created several possible entry outcomes:

Entry scenario	Commercial result
LEO prevails and no license is granted	FDA approval delayed until relevant patent barriers expire
Actavis prevails on validity	Earlier approval may become available, subject to FDA review
Actavis prevails on noninfringement	Approval may proceed if no other listed patent blocks entry
Settlement with licensed entry	Launch occurs on the negotiated date
Patent expiry before approval	Commercial entry depends mainly on FDA approval and manufacturing readiness

How strong was LEO Pharma’s Enstilar patent estate?

The estate had meaningful formulation strength but was narrower than a composition-of-matter estate covering a new active pharmaceutical ingredient.

Strengths

• It protected a commercially important combination product.
• It addressed the technical problem of calcipotriene stability.
• The formulation was tied to a marketed product with FDA approval.
• The patent claims could create a meaningful barrier to direct generic copies of the foam.
• Related litigation allowed LEO Pharma to defend the nonobviousness of the formulation technology.

Limitations

• The active ingredients were individually known.
• Combination-product patents are exposed to obviousness attacks.
• A generic applicant may design around specific excipients, solvent systems, or concentration ranges.
• Patent protection is more vulnerable after expiration of regulatory exclusivity.
• The estate does not provide the same barrier as a new molecular entity patent.

The Federal Circuit’s treatment of the ’688 patent was important because it recognized that a formulation patent can remain nonobvious even where the individual ingredients and general formulation techniques are known, provided the claimed formulation addresses a technical problem in a way that was not predictable from the prior art.[2]

Which companies were challenging Enstilar exclusivity?

Actavis Laboratories UT, Inc. was one of the generic applicants challenging LEO Pharma’s Enstilar patents. Actavis was associated with the Actavis/Teva generic pharmaceutical business, which later became part of Teva’s broader generic platform.

Teva separately litigated the same patent technology in a later case. The existence of multiple ANDA challenges indicated that Enstilar had sufficient commercial value to attract generic competition before patent expiry.

The competitive landscape included:

• LEO Pharma, the branded sponsor.
• Actavis Laboratories UT, Inc.
• Teva Pharmaceuticals USA, Inc.
• Other potential ANDA applicants evaluating the same combination and dosage form.

What was the commercial exposure from generic entry?

The principal commercial exposure was erosion of Enstilar sales in the U.S. topical psoriasis market. A generic foam could affect:

• Pharmacy substitution.
• Formulary positioning.
• Net pricing.
• Rebate requirements.
• Dermatology prescribing behavior.
• LEO Pharma’s ability to maintain premium pricing.

The impact would likely depend on whether the generic matched the branded product’s foam characteristics and whether the FDA rated it therapeutically equivalent. A first generic entrant could obtain substantial market share, while later entrants would face greater price competition.

No reliable case-specific revenue figure should be attributed to the Actavis action without linking the litigation to LEO Pharma’s reported Enstilar sales and the applicable fiscal period.

What litigation risks remained after the Actavis case?

The main risks were:

• Invalidity findings affecting the broader patent family.
• Noninfringement positions based on redesigned foam formulations.
• Separate litigation involving other Orange Book-listed patents.
• Settlement restrictions and authorized-entry provisions.
• Manufacturing differences that could create a product-specific infringement dispute.
• Regulatory delays unrelated to patent litigation.

The later Federal Circuit decision in LEO Pharma v. Teva strengthened the practical position of the ’688 patent by rejecting an overly broad obviousness analysis and emphasizing the claimed stability solution.[2] That decision increased the importance of the patent for any generic applicant using a substantially similar formulation.

Key Takeaways

• LEO Pharma v. Actavis was a Hatch-Waxman action involving generic Enstilar Foam.
• The product contained calcipotriene and betamethasone dipropionate.
• U.S. Patent No. 8,865,688 was the principal formulation patent associated with the dispute.
• The core technical issue was stability of the two-active-ingredient formulation.
• Actavis proceeded through a Paragraph IV challenge, creating potential FDA approval and market-entry consequences.
• The patent estate protected formulation technology rather than a new chemical entity.
• Related LEO Pharma litigation later produced Federal Circuit guidance supporting the nonobviousness of the formulation claims.
• Generic entry depended on patent validity, infringement, FDA approval, and any settlement or license terms.
• Biosimilar law was not relevant because Enstilar is a small-molecule topical drug.
• The principal business risk was U.S. erosion of branded foam sales after authorized or legally available generic entry.

FAQs About LEO Pharma v. Actavis Laboratories UT

What was LEO Pharma suing Actavis over?

LEO Pharma sued Actavis over its proposed generic version of Enstilar Foam, a calcipotriene and betamethasone dipropionate topical product.

Was Enstilar protected by a biologic exclusivity period?

No. Enstilar is a small-molecule topical drug approved under the NDA framework. Its exclusivity depended on drug regulatory exclusivity and listed formulation patents, not biosimilar exclusivity.

Did the case involve a Paragraph IV certification?

Yes. The litigation arose from Actavis’s challenge to listed patent rights through the Hatch-Waxman Paragraph IV process.

What made the Enstilar patent technically significant?

The patent focused on stabilizing a formulation containing calcipotriene and betamethasone dipropionate, two known active ingredients whose combination presented formulation and stability challenges.

Can a generic manufacturer avoid the Enstilar patents by changing excipients?

Potentially, but the answer depends on the precise patent claims, the proposed formulation, and whether the changes avoid literal or induced infringement. A reformulated product may still face infringement allegations if it falls within the claim language or satisfies an equivalent limitation.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Enstilar (calcipotriene and betamethasone dipropionate) foam, NDA 207589. https://www.accessdata.fda.gov/scripts/cder/daf/

2. LEO Pharma A/S v. Teva Pharmaceuticals USA, Inc., 2023 U.S. App. LEXIS 12517 (Fed. Cir. 2023).

3. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,865,688: Pharmaceutical composition comprising calcipotriol and betamethasone dipropionate. https://patents.google.com/patent/US8865688

4. LEO Pharma A/S v. Actavis Laboratories UT, Inc., No. 1:16-cv-00333-JFB-SR (D. Del. filed 2016).